US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.23 — a beat of 39.1%.
Analysts rate 10X Genomics Inc a buy (7 buy, 12 hold, 0 sell out of 19) with an average price target of $75.67.
CONFIDENT Q2 revenue grew 3% excluding settlements, while Atera orders exceeded 40 planned 2026 shipments. Management raised revenue guidance despite near-term Spatial transition pressure. Q2 FY26 Growth excludes nonrecurring settlement revenue; APAC comparisons included approximately $4 million of prior-year China purchasing pull-forward. Analysts focused on Atera manufacturing capacity, launch timing, sensitivity, utilization, and market opportunity. Management emphasized strong demand but constrained near-term production and expected Spatial transition effects. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 13.53% |
| BlackRock Inc | 8.29% |
| ARK Investment Management LLC | 7.68% |
| Vanguard Portfolio Management, LLC | 5.36% |
| Quantinno Capital Management LP | 4.20% |
| Vanguard Capital Management, LLC | 3.90% |
| T. Rowe Price Associates, Inc. | 3.48% |
| Sumitomo Mitsui Trust Group Inc | 3.22% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 10x GENOMICS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $151.0 million (down 12.7% vs Q2 2025's $172.9 million) - Products | 2026-08-07 |
| Results announced · Q3 2026 10X GENOMICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $151.0 million (down 13% vs. Q2 2025's $172.9 million); excluding | 2026-08-06 |
| Shareholder vote results · Q2 2026 10X GENOMICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 4, 2026 • Quorum achieved: 198,815,518 votes cast repr | 2026-06-08 |
| Quarterly report · Q1 2026 10X GENOMICS, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (Q1 2026): $150.8 million, down slightly from $154.9 million in | 2026-05-08 |
| Results announced · Q2 2026 10X GENOMICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $150.8 million – down 3% year-over-year, but up 9% excluding $16. | 2026-05-07 |
| Proxy statement · Q2 2026 10X GENOMICS, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Election of Class I directors (three-year terms expirin | 2026-04-24 |
| Annual report FY2025 10X GENOMICS, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue (FY 2025): $642.8 million, up 5% year-over-year from $610.8 m | 2026-02-13 |
| Results announced · Q1 2026 10X GENOMICS FY2025 EARNINGS SUMMARY HEADLINE NUMBERS • Full year 2025 revenue: $642.8 million (up 5% vs 2024's $610.8 million) • Excluding $44.1 mi | 2026-02-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 10X Genomics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.